Acid Sphingomyelinase Deficiency Ameliorates Farber Disease.

Area of Science:

• Biochemistry
• Genetics
• Pharmacology

Background:

• Farber disease is a rare, fatal lysosomal storage disorder caused by acid ceramidase deficiency, leading to ceramide accumulation.
• Currently, no effective treatments exist for Farber disease, resulting in significantly shortened lifespans for affected patients.

Purpose of the Study:

• To investigate acid sphingomyelinase as a potential therapeutic target for Farber disease.
• To evaluate the efficacy and safety of inhibiting acid sphingomyelinase in a preclinical model of Farber disease.

Main Methods:

• Developed and utilized a novel mouse model closely mimicking human Farber disease.
• Cross-bred acid ceramidase-deficient mice with acid sphingomyelinase-deficient mice to assess genetic inhibition.
• Administered the acid sphingomyelinase inhibitor amitriptyline to acid ceramidase-deficient mice to evaluate pharmacological inhibition.

Main Results:

• Genetic inhibition of acid sphingomyelinase in double-deficient mice reduced ceramide levels, ameliorated disease symptoms, and prolonged survival.
• Pharmacological inhibition using amitriptyline resulted in unexpected toxicity and mortality in acid ceramidase-deficient mice.
• Demonstrated proof-of-concept for acid sphingomyelinase as a therapeutic target, but identified significant safety concerns with specific inhibitors.

Conclusions:

• Acid sphingomyelinase inhibition represents a promising therapeutic strategy for Farber disease, potentially reducing pathology and extending lifespan.
• The acid sphingomyelinase inhibitor amitriptyline exhibits significant toxicity in the context of Farber disease, contraindicating its use.
• Further research is needed to identify safe and effective acid sphingomyelinase inhibitors for Farber disease treatment.